APA (7th ed.) Citation

AF, H., P, A., A, A., P, B., T, C., S, D., . . . M, M. (2023). Development of adverse outcome pathways relevant for the identification of substances having endocrine disruption properties Uterine adenocarcinoma as adverse outcome. EFSA journal. European Food Safety Authority, 21(2), e07744. https://doi.org/10.2903/j.efsa.2023.7744

Chicago Style (17th ed.) Citation

AF, Hernandez-Jerez, et al. "Development of Adverse Outcome Pathways Relevant for the Identification of Substances Having Endocrine Disruption Properties Uterine Adenocarcinoma as Adverse Outcome." EFSA Journal. European Food Safety Authority 21, no. 2 (2023): e07744. https://doi.org/10.2903/j.efsa.2023.7744.

MLA (9th ed.) Citation

AF, Hernandez-Jerez, et al. "Development of Adverse Outcome Pathways Relevant for the Identification of Substances Having Endocrine Disruption Properties Uterine Adenocarcinoma as Adverse Outcome." EFSA Journal. European Food Safety Authority, vol. 21, no. 2, 2023, p. e07744, https://doi.org/10.2903/j.efsa.2023.7744.